CL2017002596A1 - Neutralización del virus chikungunya mediada por anticuerpos - Google Patents

Neutralización del virus chikungunya mediada por anticuerpos

Info

Publication number
CL2017002596A1
CL2017002596A1 CL2017002596A CL2017002596A CL2017002596A1 CL 2017002596 A1 CL2017002596 A1 CL 2017002596A1 CL 2017002596 A CL2017002596 A CL 2017002596A CL 2017002596 A CL2017002596 A CL 2017002596A CL 2017002596 A1 CL2017002596 A1 CL 2017002596A1
Authority
CL
Chile
Prior art keywords
neutralization
mediated
antibody
chikungunya virus
chikungunya
Prior art date
Application number
CL2017002596A
Other languages
English (en)
Inventor
James E Crowe
Scott A Smith
Terence Dermody
Laurie Silva
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of CL2017002596A1 publication Critical patent/CL2017002596A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/181—Alphaviruses or Group A arboviruses, e.g. sindbis, VEE, EEE, WEE or semliki forest virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

<p>Anticuerpos que se unen y neutralizan al virus Chikungunya (CHIKV) y métodos para su uso.</p>
CL2017002596A 2015-04-14 2017-10-13 Neutralización del virus chikungunya mediada por anticuerpos CL2017002596A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562147354P 2015-04-14 2015-04-14

Publications (1)

Publication Number Publication Date
CL2017002596A1 true CL2017002596A1 (es) 2018-05-18

Family

ID=57126199

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002596A CL2017002596A1 (es) 2015-04-14 2017-10-13 Neutralización del virus chikungunya mediada por anticuerpos

Country Status (28)

Country Link
US (2) US10787503B2 (es)
EP (1) EP3283101A4 (es)
JP (3) JP6979875B2 (es)
KR (2) KR20230087616A (es)
CN (2) CN107708726B (es)
AR (1) AR104264A1 (es)
AU (2) AU2016250188C1 (es)
BR (1) BR112017021952A2 (es)
CA (2) CA3176525A1 (es)
CL (1) CL2017002596A1 (es)
CO (1) CO2017010316A2 (es)
CR (2) CR20170518A (es)
DO (1) DOP2017000236A (es)
EA (1) EA037060B1 (es)
EC (1) ECSP17075750A (es)
HK (1) HK1246671A1 (es)
IL (2) IL290449B2 (es)
MA (1) MA41517A (es)
MX (2) MX2017013286A (es)
MY (1) MY191666A (es)
NZ (1) NZ736445A (es)
PE (2) PE20220297A1 (es)
PH (1) PH12017501865A1 (es)
SG (2) SG11201708152SA (es)
TN (1) TN2017000438A1 (es)
TW (2) TW202248210A (es)
UA (1) UA125206C2 (es)
WO (1) WO2016168417A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11286295B2 (en) 2016-10-20 2022-03-29 Sanofi Anti-CHIKV monoclonal antibodies directed against the E2 structural protein
KR102029394B1 (ko) * 2017-11-14 2019-10-07 재단법인 바이오나노헬스가드연구단 치쿤구니아 바이러스 감염 진단용 단일클론항체, 이를 생산하는 하이브리도마 및 이를 이용한 치쿤구니아 바이러스 감염 진단 방법
WO2019136241A1 (en) 2018-01-05 2019-07-11 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
US11851478B2 (en) 2018-01-05 2023-12-26 Vanderbilt University Antibody-mediated neutralization of chikungunya virus
JP6906207B2 (ja) * 2018-02-09 2021-07-21 国立大学法人大阪大学 チクングニアウイルス検出用免疫クロマト分析装置
JP7359390B2 (ja) * 2018-02-09 2023-10-11 国立大学法人大阪大学 チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
WO2019236875A1 (en) * 2018-06-06 2019-12-12 Albert Einstein College Of Medicine, Inc. Antibodies or antibody-fragments thereof targeting alphaviruses, and compositions and methods comprising same
US20230065377A1 (en) * 2019-08-31 2023-03-02 Vanderbilt University Human antibodies to alphaviruses
KR102202082B1 (ko) * 2019-09-25 2021-01-11 충북대학교 산학협력단 치쿤군야 바이러스의 외피단백질 도메인 ⅱ에 대해 특이적으로 결합하는 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
CN110922478B (zh) * 2019-12-07 2021-07-30 中国人民解放军军事科学院军事医学研究院 针对特异表位的抗基孔肯雅热的全人源单克隆抗体及应用
WO2022101805A1 (en) * 2020-11-13 2022-05-19 Emergent Biosolutions Canada Inc. Hyperimmune globulins for treatment of chikungunya virus infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2598966A1 (en) 2007-09-07 2009-03-07 Institut Pasteur Anti-chikungunya monoclonal antibodies and uses thereof
WO2010014854A2 (en) * 2008-07-31 2010-02-04 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
WO2011124635A1 (en) 2010-04-07 2011-10-13 Humalys Binding molecules against chikungunya virus and uses thereof
EP3021868A4 (en) * 2013-07-19 2017-03-01 Integral Molecular, Inc. Antibodies against chikungunya virus and uses thereof
US11286295B2 (en) * 2016-10-20 2022-03-29 Sanofi Anti-CHIKV monoclonal antibodies directed against the E2 structural protein

Also Published As

Publication number Publication date
AU2016250188B2 (en) 2022-02-03
AR104264A1 (es) 2017-07-05
AU2016250188A1 (en) 2017-11-02
US11345743B2 (en) 2022-05-31
NZ736445A (en) 2023-06-30
EA201792220A1 (ru) 2018-03-30
TW202248210A (zh) 2022-12-16
CN114478756A (zh) 2022-05-13
US20200277359A1 (en) 2020-09-03
KR102541905B1 (ko) 2023-06-12
BR112017021952A2 (pt) 2018-07-10
KR20180004403A (ko) 2018-01-11
DOP2017000236A (es) 2017-12-15
MX2017013286A (es) 2018-06-19
IL254891A0 (en) 2017-12-31
CA2982491C (en) 2023-08-29
TW201643189A (zh) 2016-12-16
CA3176525A1 (en) 2016-10-20
EP3283101A2 (en) 2018-02-21
JP2022174144A (ja) 2022-11-22
SG11201708152SA (en) 2017-11-29
PH12017501865A1 (en) 2018-03-05
KR20230087616A (ko) 2023-06-16
EA037060B1 (ru) 2021-02-01
EP3283101A4 (en) 2019-01-16
UA125206C2 (uk) 2022-02-02
JP2018520334A (ja) 2018-07-26
IL290449B2 (en) 2024-04-01
WO2016168417A2 (en) 2016-10-20
JP2021144047A (ja) 2021-09-24
IL290449B1 (en) 2023-12-01
JP6979875B2 (ja) 2021-12-15
US10787503B2 (en) 2020-09-29
TWI772257B (zh) 2022-08-01
IL290449A (en) 2022-04-01
MX2021013207A (es) 2021-12-10
US20180079802A1 (en) 2018-03-22
TN2017000438A1 (en) 2019-04-12
MY191666A (en) 2022-07-06
CN107708726B (zh) 2022-01-14
CN107708726A (zh) 2018-02-16
CO2017010316A2 (es) 2017-12-15
PE20220297A1 (es) 2022-03-07
ECSP17075750A (es) 2018-02-28
AU2022202819A1 (en) 2022-05-19
MA41517A (fr) 2017-12-19
AU2016250188C1 (en) 2022-08-11
PE20180171A1 (es) 2018-01-22
IL254891B (en) 2022-03-01
CR20170518A (es) 2018-01-25
CA2982491A1 (en) 2016-10-20
SG10202107295XA (en) 2021-08-30
HK1246671A1 (zh) 2018-09-14
CR20210438A (es) 2021-10-04
WO2016168417A3 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
CL2017002596A1 (es) Neutralización del virus chikungunya mediada por anticuerpos
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CY1121893T1 (el) Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων
CL2017001408A1 (es) Anticuerpos anti-cd79b y métodos de uso
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
CY1121542T1 (el) Μορια αντισωματων σε pd-1 και χρηση αυτων
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
CL2017002401A1 (es) Anticuerpos contra icos
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
NI201800055A (es) Anticuerpos que se unen específicamente a pd-1 y sus usos.
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
CL2017000888A1 (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CR20190271A (es) Anticuerpos antitau y métodos de uso
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
CL2016002156A1 (es) Anticuerpo que une erbb-2 y erbb-3
PE20210648A1 (es) Anticuerpos anti-cd3 y metodos de uso
CL2016002257A1 (es) Anticuerpos anti-mcam y métodos de uso asociados
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
CL2018001139A1 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos.
CL2018000298A1 (es) Anticuerpos anti-cd154 y métodos de uso de estos.